IBDEI1Z9 ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,33556,1,4,0)
 ;;=4^E66.9
 ;;^UTILITY(U,$J,358.3,33556,2)
 ;;=^5002832
 ;;^UTILITY(U,$J,358.3,33557,0)
 ;;=E74.39^^131^1672^35
 ;;^UTILITY(U,$J,358.3,33557,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33557,1,3,0)
 ;;=3^Intestinal Carbohydrate Absorption Disorder NEC
 ;;^UTILITY(U,$J,358.3,33557,1,4,0)
 ;;=4^E74.39
 ;;^UTILITY(U,$J,358.3,33557,2)
 ;;=^5002928
 ;;^UTILITY(U,$J,358.3,33558,0)
 ;;=E83.30^^131^1672^46
 ;;^UTILITY(U,$J,358.3,33558,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33558,1,3,0)
 ;;=3^Phosphorus Metabolism Disorder,Unspec
 ;;^UTILITY(U,$J,358.3,33558,1,4,0)
 ;;=4^E83.30
 ;;^UTILITY(U,$J,358.3,33558,2)
 ;;=^5002997
 ;;^UTILITY(U,$J,358.3,33559,0)
 ;;=E83.51^^131^1672^28
 ;;^UTILITY(U,$J,358.3,33559,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33559,1,3,0)
 ;;=3^Hypocalcemia
 ;;^UTILITY(U,$J,358.3,33559,1,4,0)
 ;;=4^E83.51
 ;;^UTILITY(U,$J,358.3,33559,2)
 ;;=^60542
 ;;^UTILITY(U,$J,358.3,33560,0)
 ;;=E83.52^^131^1672^26
 ;;^UTILITY(U,$J,358.3,33560,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33560,1,3,0)
 ;;=3^Hypercalcemia
 ;;^UTILITY(U,$J,358.3,33560,1,4,0)
 ;;=4^E83.52
 ;;^UTILITY(U,$J,358.3,33560,2)
 ;;=^59932
 ;;^UTILITY(U,$J,358.3,33561,0)
 ;;=E87.5^^131^1672^27
 ;;^UTILITY(U,$J,358.3,33561,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33561,1,3,0)
 ;;=3^Hyperkalemia
 ;;^UTILITY(U,$J,358.3,33561,1,4,0)
 ;;=4^E87.5
 ;;^UTILITY(U,$J,358.3,33561,2)
 ;;=^60041
 ;;^UTILITY(U,$J,358.3,33562,0)
 ;;=E89.2^^131^1672^48
 ;;^UTILITY(U,$J,358.3,33562,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33562,1,3,0)
 ;;=3^PostProcedural Hypoparathyroidism
 ;;^UTILITY(U,$J,358.3,33562,1,4,0)
 ;;=4^E89.2
 ;;^UTILITY(U,$J,358.3,33562,2)
 ;;=^5003037
 ;;^UTILITY(U,$J,358.3,33563,0)
 ;;=E89.6^^131^1672^47
 ;;^UTILITY(U,$J,358.3,33563,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33563,1,3,0)
 ;;=3^PostProcedural Adrenocortical Hypofunction
 ;;^UTILITY(U,$J,358.3,33563,1,4,0)
 ;;=4^E89.6
 ;;^UTILITY(U,$J,358.3,33563,2)
 ;;=^5003042
 ;;^UTILITY(U,$J,358.3,33564,0)
 ;;=L68.0^^131^1672^25
 ;;^UTILITY(U,$J,358.3,33564,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33564,1,3,0)
 ;;=3^Hirsutism
 ;;^UTILITY(U,$J,358.3,33564,1,4,0)
 ;;=4^L68.0
 ;;^UTILITY(U,$J,358.3,33564,2)
 ;;=^5009262
 ;;^UTILITY(U,$J,358.3,33565,0)
 ;;=M80.00XA^^131^1672^2
 ;;^UTILITY(U,$J,358.3,33565,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33565,1,3,0)
 ;;=3^Age-Related Osteoporosis w/ Fx,Unspec Site,Init Encntr
 ;;^UTILITY(U,$J,358.3,33565,1,4,0)
 ;;=4^M80.00XA
 ;;^UTILITY(U,$J,358.3,33565,2)
 ;;=^5013363
 ;;^UTILITY(U,$J,358.3,33566,0)
 ;;=M81.0^^131^1672^3
 ;;^UTILITY(U,$J,358.3,33566,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33566,1,3,0)
 ;;=3^Age-Related Osteoporosis w/o Fx
 ;;^UTILITY(U,$J,358.3,33566,1,4,0)
 ;;=4^M81.0
 ;;^UTILITY(U,$J,358.3,33566,2)
 ;;=^5013555
 ;;^UTILITY(U,$J,358.3,33567,0)
 ;;=M85.80^^131^1672^44
 ;;^UTILITY(U,$J,358.3,33567,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33567,1,3,0)
 ;;=3^Osteopenia,Unspec Site
 ;;^UTILITY(U,$J,358.3,33567,1,4,0)
 ;;=4^M85.80
 ;;^UTILITY(U,$J,358.3,33567,2)
 ;;=^5014473
 ;;^UTILITY(U,$J,358.3,33568,0)
 ;;=N62.^^131^1672^24
 ;;^UTILITY(U,$J,358.3,33568,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33568,1,3,0)
 ;;=3^Gynecomastia
 ;;^UTILITY(U,$J,358.3,33568,1,4,0)
 ;;=4^N62.
 ;;^UTILITY(U,$J,358.3,33568,2)
 ;;=^5015790
 ;;^UTILITY(U,$J,358.3,33569,0)
 ;;=E10.43^^131^1672^6
 ;;^UTILITY(U,$J,358.3,33569,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33569,1,3,0)
 ;;=3^DM Type 1 w/ Diabetic Autonomic Polyneuropathy
 ;;^UTILITY(U,$J,358.3,33569,1,4,0)
 ;;=4^E10.43
